ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
전임상 자산 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.8%로 92억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 정밀의료와 개인화 치료, AI와 머신러닝의 통합, 바이오뱅크의 확대, 희귀질환에 대한 주력, 정부의 대처와 자금 조달에 기인한다고 생각됩니다. 예측 기간의 주요 동향에는 고급 이미징 기술의 출현, 3D 오가노이드 모델, 멀티오믹스 통합, 예측 모델 강화, 자동화, 고처리량 스크리닝 등이 포함됩니다.
향후 5년간의 성장률 9.8%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과는 중국과 네덜란드에서 수입되는 트랜스제닉 동물 모델 및 생물반응기의 비용을 증가시키고, 연구 일정을 늦추고, 연구 개발비를 증가시킬 수 있기 때문에 미국의 의약품 개발을 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
약물 발견의 증가 속도는 전임상 자산 시장의 향후 성장을 뒷받침할 것으로 예측됩니다. 의약품은 의약품이 될 수 있는 화학물질을 식별하는 과정이며, 새로운 의약품 후보를 발견하는 것을 포함합니다. 이 틀 내에서 전임상 자산은 임상개발 후보가 되는 분자의 선정을 지원하는 데 필수적인 데이터와 증거를 제공함으로써 중요한 역할을 합니다. 예를 들어 2023년 6월, 벨기에에 본부를 둔 제약업계를 대표하는 단체인 유럽제약단체연합회(EFPIA)는 유럽 제약업계의 현저한 성장을 보고하고 생산액은 2021년 3,524억 8,000만 달러에서 2022년 3,699억 5천만 달러로 생산이 증가하는 등 상당한 성장을 기록했다고 보고했습니다. 그 결과, 약물 발견의 증가가 전임상 자산 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 전임상 자산 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 전임상 자산 시장 : 성장률 분석
세계의 전임상 자산 시장 실적 : 규모와 성장, 2019-2024
세계의 전임상 자산 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 전임상 자산 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 전임상 자산 시장 : 서비스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
바이오 분석과 DMPK(약물 대사 및 약동학) 연구
독성시험
화합물 관리
안전 약리학
기타 서비스
세계의 전임상 자산 시장 : 모델 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
환자 유래 오가노이드(PDO) 모델
환자 유래 이종 이식 모델
세계의 전임상 자산 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
바이오의약품기업
정부기관
기타 최종 사용자
세계의 전임상 자산 시장 : 세분화 바이오 분석 및 DMPK(약물 대사 및 약물동태) 연구(서비스별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
약동학(PK) 연구
약역학(PD) 연구
생체분석법 개발
세계의 전임상 자산 시장 : 세분화 독성 시험(서비스별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
급성독성시험
만성독성시험
유전독성시험
발암성 시험
세계의 전임상 자산 시장 : 세분화 화합물 관리(서비스별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
화합물 라이브러리 관리
샘플의 보관과 회수
높은 처리량 스크리닝 지원
세계의 전임상 자산 시장 : 세분화 안전성 약리학(서비스별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
심혈관 안전성 평가
신경독성 평가
호흡기 안전성 평가
세계의 전임상 자산 시장 : 세분화 기타 서비스(서비스별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
규제 지원
전임상 연구 설계 및 컨설팅
커스텀 어세이 개발
제7장 지역별/국가별 분석
세계의 전임상 자산 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 전임상 자산 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
전임상 자산 시장 : 경쟁 구도
전임상 자산 시장 : 기업 프로파일
Laboratory Corporation of America : 개요, 제품 및 서비스, 전략 및 재무 분석
IQVIA Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
ICON PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Eurofins Scientific SE : 개요, 제품 및 서비스, 전략 및 재무 분석
PPD Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
SGS SA
WuXi AppTec Co. Ltd.
Intertrek Group PLC
Charles River Laboratories International Inc.
Medpace Inc.
Pharmaron Beijing Co. Ltd.
Evotec SE
GenScript Biotech Corporation
Inotiv Inc.
SRI International Inc.
Shanghai Medicilon Inc.
Biocytogen Pharmaceuticals Beijing Co. Ltd.
AmplifyBio LLC
BioReliance Corporation
Pharmalegacy Laboratories Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
전임상 자산 시장 2029 : 새로운 기회를 제공하는 국가
전임상 자산 시장 2029 : 새로운 기회를 제공하는 부문
전임상 자산 시장 2029 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
A preclinical asset encompasses all clinical trial supplies or equipment utilized during the preclinical development phase, bridging the gap between drug discovery in the laboratory and the commencement of human clinical trials. This preliminary stage involves essential feasibility assessments, iterative evaluations, and the gathering of safety data, primarily conducted on laboratory animals.
The primary categories of preclinical asset services include bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK studies play a pivotal role in the drug development process, focusing on evaluating the pharmacokinetic and drug metabolism characteristics of potential new drugs. Various models, such as patient-derived organoid (PDO) models and patient-derived xenograft models, are employed by diverse end-users, including biopharmaceutical companies, government institutes, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The preclinical assets market research report is one of a series of new reports from The Business Research Company that provides preclinical assets market statistics, including preclinical assets industry global market size, regional shares, competitors with a preclinical assets market share, detailed preclinical assets market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. This preclinical assets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The preclinical assets market size has grown strongly in recent years. It will grow from $5.87 billion in 2024 to $6.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to drug development needs, advancements in biotechnology, regulatory requirements, research funding growth, collaborative research efforts.
The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $9.28 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, ai and machine learning integration, biobanking expansion, focus on rare diseases, government initiatives and funding. Major trends in the forecast period include emergence of advanced imaging techniques, 3d organoid models, multi-omics integration, enhanced predictive models, automation and high throughput screening.
The forecast of 9.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. drug development by increasing costs for transgenic animal models and bioreactors imported from China and the Netherlands, potentially slowing research timelines and raising research and development expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising pace of drug discovery is anticipated to boost the growth of the preclinical asset market in the future. Drug discovery is the process of identifying chemical substances that can serve as medicinal agents and involves discovering new candidate medications. Within this framework, preclinical assets play a crucial role by providing essential data and evidence to support the selection of molecules for clinical development as candidates. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization representing the pharmaceutical sector, reported significant growth in the European pharmaceutical industry, with production increasing from $352.48 billion in 2021 to $369.95 billion in 2022. Consequently, the increase in drug discovery is driving the growth of the preclinical assets market.
The escalating need to mitigate clinical trial expenditures drives the upward momentum of the preclinical asset market. Clinical trial costs encompass the comprehensive expenses incurred in planning, executing, and managing trials aimed at assessing the safety, efficacy, and potential benefits of novel medical interventions. These trials provide critical insights into the safety, effectiveness, and potential side effects of preclinical assets, validating their therapeutic promise in human subjects. For instance, data sourced from Genetic Engineering and Biotechnology News in February 2023 underscored a substantial rise in the cost of developing new drugs among the top 20 global biopharma companies, soaring by 15% from $298 million in 2022 to approximately $2.3 billion in 2023. This increase encapsulates the expenses incurred throughout the drug development lifecycle, particularly in clinical trial phases. Hence, the mounting emphasis on reducing clinical trial costs propels the expansion of the preclinical asset market.
Product innovation has emerged as a significant trend driving growth within the preclinical assets market. Prominent players in this sector are heavily invested in pioneering new products and solutions to fortify their market position and gain a competitive edge. An illustrative case is the partnership between Charles River Laboratories International and Valo Health Inc. In April 2022, they introduced Logica, an AI-powered drug solution. This innovative offering seamlessly translates biological insights of clients into optimized preclinical assets. By amalgamating Charles River's extensive preclinical expertise with Valo's AI-driven Opal Computational Platform, Logica delivers a unified approach to drug discovery. This transformative partnership ensures the conversion of targets into candidate nominations, enhancing efficiency and yielding highly qualified leads for clients while aligning costs with value creation.
Major companies in the preclinical assets market are concentrating on establishing strategic alliances to enhance their market position. For example, in July 2023, AbbVie, a US-based pharmaceutical company, and Calibr, a leading research and drug development firm based in India, announced an expanded strategic collaboration aimed at advancing several innovative preclinical and early-stage clinical assets. This partnership builds on the previous collaboration between AbbVie and Scripps Research. Additionally, Calibr will provide AbbVie with a specific number of new discovery targets and preclinical assets of mutual interest for consideration of options.
In October 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation based in the United States, completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for a total of $11.6 billion. Through this acquisition, Pfizer obtained access to a promising portfolio of calcitonin gene-related peptide (CGRP) receptor antagonists, which encompasses Rimegepant, Zavegepant, and a collection of preclinical CGRP assets. Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company headquartered in the United States, known for its early-stage discovery program and various preclinical assets.
Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore
North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the preclinical assets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Preclinical Assets Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on preclinical assets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for preclinical assets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preclinical assets market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies; Toxicology Testing; Compound Management; Safety Pharmacology; Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model; Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies; Government Institutes; Other End-Users
Subsegments:
1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies; Pharmacodynamics (PD) Studies; Bioanalytical Method Development
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Preclinical Assets Market Characteristics
3. Preclinical Assets Market Trends And Strategies
4. Preclinical Assets Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Preclinical Assets Growth Analysis And Strategic Analysis Framework
5.1. Global Preclinical Assets PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Preclinical Assets Market Growth Rate Analysis
5.4. Global Preclinical Assets Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Preclinical Assets Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Preclinical Assets Total Addressable Market (TAM)
6. Preclinical Assets Market Segmentation
6.1. Global Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies
Toxicology Testing
Compound Management
Safety Pharmacology
Other Services
6.2. Global Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Patient Derived Organoid (PDO) Model
Patient Derived Xenograft Model
6.3. Global Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biopharmaceutical Companies
Government Institutes
Other End-Users
6.4. Global Preclinical Assets Market, Sub-Segmentation Of Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmacokinetics (PK) Studies
Pharmacodynamics (PD) Studies
Bioanalytical Method Development
6.5. Global Preclinical Assets Market, Sub-Segmentation Of Toxicology Testing, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Toxicity Testing
Chronic Toxicity Testing
Genotoxicity Testing
Carcinogenicity Testing
6.6. Global Preclinical Assets Market, Sub-Segmentation Of Compound Management, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Compound Library Management
Sample Storage And Retrieval
High-Throughput Screening Support
6.7. Global Preclinical Assets Market, Sub-Segmentation Of Safety Pharmacology, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiovascular Safety Assessments
Neurotoxicity Evaluations
Respiratory Safety Evaluations
6.8. Global Preclinical Assets Market, Sub-Segmentation Of Other Services, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Regulatory Support
Preclinical Study Design And Consulting
Custom Assay Development
7. Preclinical Assets Market Regional And Country Analysis
7.1. Global Preclinical Assets Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Preclinical Assets Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
